

AMS.PM-CAR1007

For immunotherapy discovery

Ready-to-Use CAR-T Cells and Target Cell Lines

Promab Biotechnologies' CAR-T new product development programs are being designed for pre-clinical and future clinical applications. CAR-T cells can be used for:

1. Compound screening
2. Antibody screening
3. Co-stimulatory and activation domain comparison
4. Personalized medicine and donor variations for CAR-T screening
5. Checkpoint inhibitors
6. Safety switches and regulators of CAR-T functions
7. Pre-clinical *in vivo* models
8. Treg and T memory cells in CAR-T setting
9. CAR-T signaling, tumor microenvironment
10. Proof of concept studies for clinical trials

The structure of CAR from Promab's available CAR-T cells targeting CD19 antigen

B-lymphocyte antigen CD19, also known as CD19 (Cluster of Differentiation 19), is a protein that in humans is encoded by the CD19 gene. It is found on the surface of B-cells, a type of white blood cell and is used as a tumor antigen for CAR-T immunotherapy.

The flag tag is inserted for additional detection of scFv with Flag tag antibody.




Figure 1. CAR-T cells expressing the above constructs are available from Promab targeting CD19 antigen. ScFv, single chain variable fragment. Flag tag is C-terminal to CD19 scFv.

AMSBIO | www.amsbio.com | info@amsbio.com

 **UK & Rest of the World**
184 Park Drive, Milton Park
Abingdon OX14 4SE, UK
T: +44 (0)1235 828 200
F: +44 (0) 1235 820 482

 **North America**
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

 **Germany**
Bockenheimer Landstr. 17/19
60325 Frankfurt/Main
T: +49 (0) 69 779099
F: +49 (0) 69 13376880

 **Switzerland**
Centro Nord-Sud 2E
CH-6934 Bioggio-Lugano
T: +41(0) 91 604 55 22
F: +41(0) 91 605 17 85